), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a ...
NEW YORK, NY--(Marketwired - Mar 12, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells ...
NEW YORK--(BUSINESS WIRE)--Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its ...
NEW YORK, Oct. 4, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it has been granted a Research Tissue Banking License by the New York State ...
NEW YORK, Oct. 9, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has been successful in manufacturing stromal vascular cells from Non-Living adipose ...
According to Dr. Zain Khalpey's conclusions in the clinical communications to The American Journal of Medicine, "We postulate that the intramyocardial administration of multi-potent adipose-derived ...
NEW YORK--(BUSINESS WIRE)-- IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“IntelliCell”) or the (“Company”), December 27, 2010 IntelliCell filed its patent application with the US ...
The deal, worth $700,000 plus a royalty stream of 12.5%, covers Australia and New Zealand. Cell-Innovations will market the stromal vascular fraction (SVF) manufacturing technology of IntelliCell ...
Joint pain took over Jim Cole’s life so much so that he decided to try Enbrel, a drug that he said ended up causing him more pain than relief. He stopped playing golf, his favorite past time, and didn ...
NEW YORK--(BUSINESS WIRE)--IntelliCell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“IntelliCell”) or the (“Company”), IntelliCell has licensed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results